Literature DB >> 8831503

Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta.

C R Bacon1, N R Cary, A P Davenport.   

Abstract

The aim of this study was to determine whether there is an alteration in the distribution or quantity of endothelin (ET) peptide or receptor subtypes in human atherosclerotic arteries. Levels of endogenous ET and big ET-1 detectable by radioimmunoassay in human aorta containing raised atherosclerotic plaques were significantly higher than those in histologically normal tissue (Student's t test, P < .01). Immunohistochemistry revealed ET-like immunoreactivity in endothelial cells lining the vessel lumen, neovascularization, recanalization of organized thrombus, and regions rich in macrophages. Little immunoreactivity was associated with vascular smooth muscle cells (VSMCs). Saturation binding assays with [125I]ET-1 indicated comparable affinities and maximal densities of receptors in the media of diseased and normal coronary arteries. Quantitative autoradiography with subtype-selective radioligands revealed similar small proportions of ETB receptors in the diseased and normal arterial media. In arteries with early and late disease, ETA receptors were localized to medial smooth muscle but were lacking in the VSMCs of the intimal layer, where ETB receptors were absent. ETB receptors were detected on perivascular nerves and lymphoid aggregates. In atherosclerotic arteries, microautoradiography localized ETB receptors to neovascularization and, interestingly, to macrophages. The results of this study indicate that there is an increase in ET and big ET-1 associated with fully developed atherosclerotic plaques. It is likely that this is derived from endothelial cells and macrophages but not VSMCs. ETA receptors predominate in the media of both normal and diseased arteries. ET receptors are deficient in intimal smooth muscle, and ETB receptors, where present, are found on endothelial cells and macrophages.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831503     DOI: 10.1161/01.res.79.4.794

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  24 in total

Review 1.  Secretory pathways in endothelin synthesis.

Authors:  F D Russell; A P Davenport
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 2.  Coronary endothelial function in health and disease.

Authors:  J C Burnett
Journal:  Drugs       Date:  1997       Impact factor: 9.546

3.  Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system.

Authors:  K E Wiley; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

4.  A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression.

Authors:  Rajat M Gupta; Joseph Hadaya; Aditi Trehan; Seyedeh M Zekavat; Carolina Roselli; Derek Klarin; Connor A Emdin; Catharina R E Hilvering; Valerio Bianchi; Christian Mueller; Amit V Khera; Russell J H Ryan; Jesse M Engreitz; Robbyn Issner; Noam Shoresh; Charles B Epstein; Wouter de Laat; Jonathan D Brown; Renate B Schnabel; Bradley E Bernstein; Sekar Kathiresan
Journal:  Cell       Date:  2017-07-27       Impact factor: 41.582

5.  Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver.

Authors:  Peter Johnström; Tim D Fryer; Hugh K Richards; Janet J Maguire; John C Clark; John D Pickard; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2010-02       Impact factor: 8.739

6.  Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology.

Authors:  R Scotland; P Vallance; A Ahluwalia
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 7.  Is urotensin-II the new endothelin?

Authors:  Janet J Maguire; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

8.  Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery.

Authors:  K E Wiley; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

9.  Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

10.  Heart ischaemia-reperfusion induces local up-regulation of vasoconstrictor endothelin ETB receptors in rat coronary arteries downstream of occlusion.

Authors:  G F Skovsted; L S Kruse; R Larsen; A F Pedersen; S Trautner; M Sheykhzade; L Edvinsson
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.